Erowid
 
 
Plants - Drugs Mind - Spirit Freedom - Law Arts - Culture Library  
Ltd Ed 'Solve et Elucido' Art Giclee
This reverberating psychedelic giclee print is a gift for a
$500 donation to Erowid. 12" x 12", stretched on canvas, the
image wraps around the sides of the 1" thick piece. Signed
by artist Vibrata, and Erowid founders Earth & Fire.
MBDB Journal Articles & Abstracts


General
Pharmacology
Drug Testing


GENERAL

Deaths Associated with MBDB Misuse,
by N. Carter; G.N. Rutty; C.M. Milroy; A.R.W. Forrest
Int. J. Legal Med. Vol 113; 2000, 68-170
[ View Reference ]

Derivatives of 1-(1,3-Benzodioxol-5-yl-2-butanamine: Representatives of a Novel Therapeutic Class,
by D.E. Nichols; A.J. Hoffman; R.A. Oberlender; P. Jacob III; A.T. Shulgin
J. Med. Chem Vol 29; 1986, 2009-2015

Hallucinogenic and Stimulatory Amphetamine Derivatives: Fingerprinting DOM, DOI, DOB, MDMA, and MBDB by Spectral Analysis of Brain Field Potentials in the Freely Moving Rat (Tele-Stereo-EEG),
by W. Dimpfel; M. Sp¸ler, and D.E. Nichols
Psychopharmacology Vol 98; 1989, 297-303
[ View Reference ]

Microdialysis Studies on 3,4-Methylenedioxyamphetamine and Structurally Related Analogues,
by J.F. Nash; D.E. Nichols
Europ. J. Pharmacol Vol 200; 1991, 53-58
[ View Reference ]

(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a Discriminative Stimulus in Studies of 3,4-methylenedioxymethamphetamine-Like Behavioural Activity,
by R. Oberlender; D.E. Nichols
J. Pharm. Exptl. Therap Vol 225; 1990, 1098-1106
[ View Reference ]

Reinforcing Effects of Certain Serotonin-Releasing Amphetamine Derivatives,
by D. Marona-Lewicka; G.S. Rhee; J.E. Sprague; D.E. Nichols
Pharmacol Biochem Behav Vol 53 (No 1) Jan 1996, 99-105
[ View Reference ]



	


PHARMACOLOGY

Differences Between the Mechanism of Action of MDMA, MBDB and the Classic Hallucinogens,
by D. Nichols
Journal of Psychoactive Drugs Vol 18 (No 4) 1986
[ View Reference ]

The Effects of MDMA and Other Methylenedioxy-substituted Phenylalkylamines on the Structure of Rat Locomotor Activity,
by M.P. Paulus; M.A. Geyer
Neuropsychopharm Vol 7; 1992, 15-31
[ View Reference ]

Excretion of MBDB and BDB in Urine, Saliva, and Sweat Following Single Oral Administration,
by P. Kintz
Journal of Analytical Toxicology Vol 21 (No 7) Nov/Dec 1997, 570–575

The Neuroendocrine Pharmacology of Three Serotonin Releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAI) and p-methylthioamphetamine (MTA),
by Q. Li, I. Murakami, S. Stall, A.D. Levy, M.S. Brownfield, D.E. Nichols, and L.D. Van de Kar
J. Pharmacol. Exp. Ther. Vol 279; 1996, 1261-1267



	


DRUG TESTING

Identification of N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) in urine from drug users,
by R Kronstrand
J Anal Toxicol Vol 20 (No 6) 1996, 512-6
[ View Reference ]